Susquehanna International Group’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$604M Sell
2,775,900
-878,500
-24% -$195M 0.07% 228
2025
Q4
$835M Sell
3,654,400
-1,306,200
-26% -$298M 0.1% 159
2025
Q3
$1.15B Sell
4,960,600
-334,100
-6% -$68M 0.13% 120
2025
Q2
$983M Buy
5,294,700
+440,800
+9% +$81.9M 0.14% 111
2025
Q1
$1.02B Sell
4,853,900
-180,500
-4% -$35.1M 0.17% 88
2024
Q4
$895M Buy
5,034,400
+1,040,400
+26% +$191M 0.14% 107
2024
Q3
$789M Buy
3,994,000
+850,600
+27% +$159M 0.14% 121
2024
Q2
$539M Buy
3,143,400
+166,900
+6% +$27.6M 0.1% 153
2024
Q1
$542M Sell
2,976,500
-1,131,600
-28% -$195M 0.09% 161
2023
Q4
$637M Sell
4,108,100
-261,800
-6% -$38.2M 0.12% 128
2023
Q3
$651M Buy
4,369,900
+654,800
+18% +$96.1M 0.14% 95
2023
Q2
$501M Sell
3,715,100
-194,100
-5% -$28.5M 0.1% 132
2023
Q1
$623M Sell
3,909,200
-237,500
-6% -$36.3M 0.13% 102
2022
Q4
$670M Buy
4,146,700
+852,100
+26% +$131M 0.17% 85
2022
Q3
$442M Sell
3,294,600
-1,483,700
-31% -$213M 0.11% 136
2022
Q2
$732M Buy
4,778,300
+151,500
+3% +$23.1M 0.18% 66
2022
Q1
$750M Sell
4,626,800
-117,500
-2% -$17.1M 0.13% 103
2021
Q4
$642M Sell
4,744,300
-22,400
-0.5% -$2.65M 0.1% 155
2021
Q3
$514M Sell
4,766,700
-1,337,900
-22% -$153M 0.07% 233
2021
Q2
$688M Buy
6,104,600
+2,203,700
+56% +$248M 0.1% 160
2021
Q1
$422M Buy
3,900,900
+541,500
+16% +$57.9M 0.07% 248
2020
Q4
$360M Buy
3,359,400
+482,500
+17% +$46.4M 0.06% 245
2020
Q3
$252M Sell
2,876,900
-1,775,400
-38% -$167M 0.05% 285
2020
Q2
$457M Buy
4,652,300
+264,400
+6% +$23.3M 0.11% 146
2020
Q1
$334M Buy
4,387,900
+501,000
+13% +$42.7M 0.11% 152
2019
Q4
$344M Sell
3,886,900
-790,700
-17% -$65.6M 0.1% 158
2019
Q3
$354M Buy
4,677,600
+1,126,000
+32% +$77.2M 0.12% 137
2019
Q2
$258M Buy
3,551,600
+1,685,600
+90% +$132M 0.09% 175
2019
Q1
$150M Sell
1,866,000
-2,414,700
-56% -$198M 0.06% 266
2018
Q4
$395M Buy
4,280,700
+1,397,700
+48% +$123M 0.16% 100
2018
Q3
$273M Buy
2,883,000
+32,600
+1% +$3.09M 0.09% 184
2018
Q2
$264M Buy
2,850,400
+185,600
+7% +$18.1M 0.09% 184
2018
Q1
$252M Sell
2,664,800
-373,600
-12% -$41M 0.09% 179
2017
Q4
$294M Sell
3,038,400
-236,700
-7% -$22.3M 0.1% 159
2017
Q3
$291M Sell
3,275,100
-1,482,200
-31% -$113M 0.11% 148
2017
Q2
$345M Sell
4,757,300
-1,060,800
-18% -$71.3M 0.15% 106
2017
Q1
$379M Buy
5,818,100
+1,778,000
+44% +$112M 0.19% 83
2016
Q4
$253M Buy
4,040,100
+872,900
+28% +$53.3M 0.13% 127
2016
Q3
$200M Sell
3,167,200
-320,100
-9% -$20.7M 0.1% 161
2016
Q2
$216M Buy
3,487,300
+1,050,100
+43% +$64M 0.12% 140
2016
Q1
$139M Sell
2,437,200
-165,000
-6% -$9.2M 0.07% 219
2015
Q4
$154M Sell
2,602,200
-1,022,900
-28% -$58.9M 0.07% 240
2015
Q3
$197M Sell
3,625,100
-238,500
-6% -$15.5M 0.09% 202
2015
Q2
$260M Buy
3,863,600
+793,600
+26% +$51.8M 0.11% 146
2015
Q1
$180M Sell
3,070,000
-698,300
-19% -$42.2M 0.08% 221
2014
Q4
$247M Buy
3,768,300
+807,600
+27% +$50.9M 0.1% 193
2014
Q3
$171M Buy
2,960,700
+1,013,500
+52% +$56.3M 0.07% 250
2014
Q2
$110M Sell
1,947,200
-263,300
-12% -$13.8M 0.05% 343
2014
Q1
$114M Buy
2,210,500
+298,200
+16% +$15.1M 0.05% 309
2013
Q4
$101M Sell
1,912,300
-274,500
-13% -$13.5M 0.05% 350
2013
Q3
$97.8M Buy
2,186,800
+740,400
+51% +$32.8M 0.05% 321
2013
Q2
$59.8M Buy
+1,446,400
New +$63.3M 0.03% 479

Other funds holding ABBV

Susquehanna International Group's ABBV Position: Q1 2026 in Review

Susquehanna International Group increased its AbbVie (ABBV) stake by 51% in Q1 2026, buying an estimated $32.2M and bringing the position to 431,015 shares worth $93.7M. The position accounts for 0.01% of the portfolio, ranked #873.

Susquehanna International Group first reported a position in ABBV in Q2 2013 and has held it in 49 quarters since. The position peaked at $349M in Q4 2021. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Susquehanna International Group held 431,015 shares of AbbVie worth $93.7M as of Q1 2026.
  • Susquehanna International Group bought 145,084 AbbVie shares in Q1 2026, an estimated $32.2M.
  • AbbVie made up 0.01% of Susquehanna International Group's portfolio in Q1 2026, its #873 holding.
  • Susquehanna International Group first reported a position in AbbVie in Q2 2013 and has held it in 49 quarters since.
  • Susquehanna International Group's AbbVie position peaked at $349M in Q4 2021.
  • 4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.